Meeting
2022 ASCO Gastrointestinal Cancers Symposium
SONCAR study: A prospective randomized controlled study on optimized neoadjuvant chemotherapy-oxaliplatin plus CRT in patients with locally advanced rectal cancer.
Authors
Rong-Xin Zhang
Sun Yat-sen University Cancer Center, Guangzhou, China
Rong-Xin Zhang , Zhifan Zeng , Yuan-Hong Gao , Xiao-Jun Wu , Gong Chen , Liren Li , Pei-Rong Ding , Min Liu , Qiaoxuan Wang , Weiwei Xiao , Zhi-Zhong Pan , De-Sen Wan , Zhen-Hai LU
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02031939
DOI
10.1200/JCO.2022.40.4_suppl.117
Abstract #
117
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A randomized phase II trial of consolidation chemotherapy after preoperative chemoradiation (preop CRT) versus CRT alone for locally advanced rectal cancer (LARC).
First Author: Sun Young Kim
Poster
2015 ASCO Annual Meeting
S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC).
First Author: Cynthia G. Leichman
Poster
2013 Gastrointestinal Cancers Symposium
Oxaliplatin and capecitabine initially concomitant to radiotherapy then administered in the resting period in high-risk locally advanced rectal cancer.
First Author: Pei-Rong Ding
Poster
2023 ASCO Annual Meeting
Neoadjuvant short-course radiotherapy followed by chemotherapy plus camrelizumab versus long-course chemoradiotherapy followed by chemotherapy for patients with locally advanced rectal cancer: A randomized, multicenter, open-label phase 3 trial (Union).
First Author: Zhenyu Lin